GlassScriptPhysician profile
James J Kluzinski
NPI 1477567071
$3,656.95
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $199 · 2021: $250 · 2022: $450 · 2023: $1,335 · 2024: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $550.54 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $525.51 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $388.05 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $387.72 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $347.73 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $237.17 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $131.96 | 2019-2022 | |
| Amgen INC. | $117.31 | 2019-2024 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $104.57 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $96.56 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $75.27 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.82 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $55.15 | 2019-2020 | |
| Exact Sciences Corporation | $52.76 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.87 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $47.65 | 2019-2022 | |
| Amarin Pharma, INC. | $47.16 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.18 | 2022 | |
| Aimmune Therapeutics, INC. | $42.63 | 2024 | |
| Abbott Laboratories | $38.63 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $35.70 | 2022 | |
| Hologic Sales and Service, LLC | $34.87 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Janssen Pharmaceuticals, INC | $34.04 | 2019-2020 | |
| Sanofi Pasteur INC. | $31.85 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $24.84 | 2023 | |
| Avanir Pharmaceuticals, INC. | $20.24 | 2019 | |
| Dynavax Technologies Corporation | $19.00 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.37 | 2019 | |
| Shield Therapeutics INC | $15.28 | 2023 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $13.52 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kluzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.